Due to the Covid-19 virus outbreak, Evonik’s contract manufacturer had to shut-down its production facilities. Both production and shipping of the amino acid ThreAMINO® are affected and the shortage affects all regions.

Emmanuel Auer, head of Animal Nutrition Business Line at Evonik, said that “regrettably, we are facing a supply shortage for ThreAMINO®. Therefore, we have decided to send a force majeure notification to our customers with immediate effect, in accordance with our contracts. Meanwhile, we try the utmost to mitigate this situation and re-establish supply to our customers as fast as possible.”

Evonik will keep customers regularly informed as the situation develops.